vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $18.3M, roughly 1.0× ROCKWELL MEDICAL, INC.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -64.1%, a 61.1% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs -25.6%). ROCKWELL MEDICAL, INC. produced more free cash flow last quarter ($2.2M vs $-11.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs -10.1%).
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
ENTA vs RMTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $18.3M |
| Net Profit | $-11.9M | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | -60.5% | -2.2% |
| Net Margin | -64.1% | -3.0% |
| Revenue YoY | 9.8% | -25.6% |
| Net Profit YoY | 46.4% | 26.7% |
| EPS (diluted) | $-0.42 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $18.3M | ||
| Q3 25 | $15.1M | $15.9M | ||
| Q2 25 | $18.3M | $16.1M | ||
| Q1 25 | $14.9M | $18.9M | ||
| Q4 24 | $17.0M | $24.7M | ||
| Q3 24 | $14.6M | $28.3M | ||
| Q2 24 | $18.0M | $25.8M | ||
| Q1 24 | $17.1M | $22.7M |
| Q4 25 | $-11.9M | $-554.0K | ||
| Q3 25 | $-18.7M | $-1.8M | ||
| Q2 25 | $-18.3M | $-1.5M | ||
| Q1 25 | $-22.6M | $-1.5M | ||
| Q4 24 | $-22.3M | $-756.0K | ||
| Q3 24 | $-28.8M | $1.7M | ||
| Q2 24 | $-22.7M | $343.0K | ||
| Q1 24 | $-31.2M | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | -60.5% | -2.2% | ||
| Q3 25 | -121.6% | -9.9% | ||
| Q2 25 | -103.2% | -8.4% | ||
| Q1 25 | -164.3% | -7.2% | ||
| Q4 24 | -138.8% | -2.1% | ||
| Q3 24 | -204.4% | 6.8% | ||
| Q2 24 | -134.6% | 2.0% | ||
| Q1 24 | -192.1% | -5.8% |
| Q4 25 | -64.1% | -3.0% | ||
| Q3 25 | -123.6% | -11.0% | ||
| Q2 25 | -99.7% | -9.3% | ||
| Q1 25 | -151.7% | -8.0% | ||
| Q4 24 | -131.4% | -3.1% | ||
| Q3 24 | -197.3% | 5.9% | ||
| Q2 24 | -126.1% | 1.3% | ||
| Q1 24 | -182.7% | -7.6% |
| Q4 25 | $-0.42 | $-0.01 | ||
| Q3 25 | $-0.88 | $-0.05 | ||
| Q2 25 | $-0.85 | $-0.05 | ||
| Q1 25 | $-1.06 | $-0.04 | ||
| Q4 24 | $-1.05 | $-0.02 | ||
| Q3 24 | $-1.36 | $0.04 | ||
| Q2 24 | $-1.07 | $0.01 | ||
| Q1 24 | $-1.47 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.6M | $37.0M |
| Total Assets | $329.5M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $10.7M | ||
| Q3 25 | $32.3M | $13.6M | ||
| Q2 25 | $44.8M | $12.5M | ||
| Q1 25 | $60.2M | $11.4M | ||
| Q4 24 | $84.3M | $15.7M | ||
| Q3 24 | $37.2M | $12.3M | ||
| Q2 24 | $35.8M | $11.9M | ||
| Q1 24 | $63.5M | $6.6M |
| Q4 25 | $126.6M | $37.0M | ||
| Q3 25 | $64.7M | $37.0M | ||
| Q2 25 | $79.3M | $30.4M | ||
| Q1 25 | $93.5M | $31.5M | ||
| Q4 24 | $111.8M | $32.6M | ||
| Q3 24 | $128.8M | $29.1M | ||
| Q2 24 | $148.9M | $23.5M | ||
| Q1 24 | $166.1M | $20.6M |
| Q4 25 | $329.5M | $57.1M | ||
| Q3 25 | $280.7M | $57.5M | ||
| Q2 25 | $301.0M | $52.6M | ||
| Q1 25 | $323.0M | $54.0M | ||
| Q4 24 | $348.6M | $59.2M | ||
| Q3 24 | $376.7M | $57.1M | ||
| Q2 24 | $398.8M | $53.0M | ||
| Q1 24 | $413.6M | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $2.3M |
| Free Cash FlowOCF − Capex | $-11.8M | $2.2M |
| FCF MarginFCF / Revenue | -63.6% | 12.0% |
| Capex IntensityCapex / Revenue | 0.8% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $2.3M | ||
| Q3 25 | $-6.5M | $-1.3M | ||
| Q2 25 | $17.5M | $1.8M | ||
| Q1 25 | $-13.5M | $-3.5M | ||
| Q4 24 | $-16.8M | $865.0K | ||
| Q3 24 | $-10.4M | $4.3M | ||
| Q2 24 | $-14.8M | $1.4M | ||
| Q1 24 | $-28.6M | $-2.4M |
| Q4 25 | $-11.8M | $2.2M | ||
| Q3 25 | $-7.9M | $-1.5M | ||
| Q2 25 | $17.4M | $1.7M | ||
| Q1 25 | $-16.0M | $-3.5M | ||
| Q4 24 | $-25.5M | $470.0K | ||
| Q3 24 | $-19.4M | $4.1M | ||
| Q2 24 | $-21.3M | $1.2M | ||
| Q1 24 | $-30.3M | $-2.5M |
| Q4 25 | -63.6% | 12.0% | ||
| Q3 25 | -52.5% | -9.6% | ||
| Q2 25 | 94.7% | 10.5% | ||
| Q1 25 | -107.4% | -18.8% | ||
| Q4 24 | -150.6% | 1.9% | ||
| Q3 24 | -132.5% | 14.4% | ||
| Q2 24 | -118.6% | 4.5% | ||
| Q1 24 | -177.5% | -11.1% |
| Q4 25 | 0.8% | 0.5% | ||
| Q3 25 | 9.6% | 1.4% | ||
| Q2 25 | 0.8% | 1.0% | ||
| Q1 25 | 17.0% | 0.3% | ||
| Q4 24 | 51.6% | 1.6% | ||
| Q3 24 | 61.3% | 0.7% | ||
| Q2 24 | 36.4% | 1.1% | ||
| Q1 24 | 9.8% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTA
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
